Temozolomide Plus Thalidomide in Patients With Advanced Melanoma: Results of a Dose-Finding Trial - Concepedia

Concepedia

Publication | Closed Access

Temozolomide Plus Thalidomide in Patients With Advanced Melanoma: Results of a Dose-Finding Trial

66

Citations

16

References

2002

Year

Wen-Jen Hwu, Susan E. Krown, Katherine S. Panageas, Jennifer H. Menell, Paul B. Chapman, Philip O. Livingston, Linda Williams, Carolyn Quinn, Alan N. Houghton

Journal of Clinical Oncology

Abstract

The combination of temozolomide and thalidomide was well tolerated and had antitumor activity in patients with advanced melanoma, including elderly patients over 70 years old.

References

	Year	Citations
Thalidomide is an inhibitor of angiogenesis. Robert J. D’Amato, Michael Loughnan, Evelyn Flynn, Proceedings of the National Academy of Sciences AngiogenesisDevelopmental BiologyOphthalmologyVascular PharmacologyPharmacology	1994	2.5K
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Timothy M. Browder, Catherine Butterfield, Birgit M. Kräling, PubMed Tumor BiologyChemoprevention StrategyMedicineAntiangiogenic SchedulingTumor Growth	2000	1.6K
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma Mark R. Middleton, Jean‐Jacques Grob, Neil K. Aaronson, Journal of Clinical Oncology	2000	1.3K
Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. E P Sampaio, Euzenir Nunes Sarno, Ruth Galilly, The Journal of Experimental Medicine Toxic EffectsImmune RegulationImmunologyCell DeathPathology	1991	1.2K
Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse W.K. Alfred Yung, Michael D. Prados, Ricardo Yayá, Journal of Clinical Oncology	1999	757
Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset Patrick Haslett, Laura G. Corral, Matthew L. Albert, The Journal of Experimental Medicine	1998	571
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. L. Serrone, Massimo Zeuli, F M Sega, PubMed Dtic-based Combination ChemotherapyOncologyMedicineDtic Single AgentDacarbazine-based Chemotherapy	2000	350
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer Tim Eisen, Chris Boshoff, Ian Mak, British Journal of Cancer	2000	341
Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2b Steven A. Rosenberg, James Chih‐Hsin Yang, Douglas J. Schwartzentruber, Journal of Clinical Oncology	1999	316
Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade Hartmut Geitz, Stefan Handt, K. Zwingenberger Immunopharmacology Cell Surface MoleculesSignal TransductionCell InteractionCell AdhesionCell Trafficking	1996	290

Page 1